Under construction – not a live service
Sign in
Taking people in United StatesPhase 2

IMVT-1402 for adults with Graves' disease who remain overactive despite treatment

Tests IMVT-1402 in adults with Graves' disease still hyperthyroid on antithyroid medicine.

Key facts

Who runs it
Immunovant Sciences GmbH
Where
Aurora, Chapel Hill, Columbus, Concord, Dallas, Doral, El Paso, Fort Worth, Hialeah, Hickory, Houston, Irving, Jefferson City, Kansas City, Long Island City, Louisville, McKinney, Memphis, Miami, Morehead City, New Hyde Park, New York, Norfolk, Oklahoma City, Raleigh, Reno, San Antonio, St Louis, Topeka, Tucson, and Williamsville, United StatesSee the 33 sitesAlso in 18 other countries, 135 sites
Registry title
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
Status
Recruiting
Phase
Phase 2
People taking part
210 people, planned
Started
19 Jun 2025
Expected to end
May 2027
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • IMVT-1402
  • Placebo
Record updated
30 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with Graves' disease whose thyroid is still overactive despite antithyroid drug (ATD) treatment.

Age
18 to 75 years
Sex
All sexes can join.
Disease stage
Graves' disease with an overactive thyroid (hyperthyroid) despite antithyroid drug treatment.
Earlier treatment
Must have had antithyroid drug (ATD) treatment. People already successfully treated with radioactive iodine (RAI) or who had the whole thyroid removed cannot join.

Main reasons for not taking part

  • Earlier successful radioactive iodine (RAI) therapy
  • Surgery that removed the whole thyroid (total thyroidectomy)
  • Another autoimmune disease needing treatment that the study doctor judges too risky
  • Moderate-to-severe active thyroid eye disease needing urgent surgery, or planned surgery, radiation or medicine for it during the study
  • Other exclusion reasons set in the protocol

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Participants with the ability to understand the requirements of the trial, provide written informed consent, and comply with the trial protocol procedures
  • Male or female participants aged ≥ 18 years
  • Participants with diagnosis of GD who are hyperthyroid despite ATD treatment
  • Other, more specific inclusion criteria are defined in the protocol

Who cannot take part

  • Have previously been successfully treated with radioactive iodine (RAI) therapy or have undergone total thyroidectomy
  • Have an autoimmune disease other than GD requiring treatment that, in the Investigator's judgment, puts the participant at undue risk
  • Have moderate-to-severe active thyroid eye disease (TED) and are expected to require immediate surgical intervention and/or are planning corrective surgery/irradiation or medical therapy for TED during study participation
  • Additional exclusion criteria are defined in the protocol

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Where in United States

Also in 18 other countries, 135 sites

  • Aurora, ColoradoHospital not named in the registryTaking people
  • Chapel Hill, North CarolinaHospital not named in the registryTaking people
  • Columbus, GeorgiaHospital not named in the registryTaking people
  • Concord, CaliforniaHospital not named in the registryTaking people
  • Dallas, TexasHospital not named in the registryTaking people
  • Doral, FloridaHospital not named in the registryTaking people
  • El Paso, TexasHospital not named in the registryTaking people
  • Fort Worth, TexasHospital not named in the registryTaking people
  • Hialeah, FloridaHospital not named in the registryTaking people
  • Hickory, North CarolinaHospital not named in the registryTaking people
  • Houston, TexasHospital not named in the registryTaking people
  • Houston, TexasHospital not named in the registryTaking people
  • Irving, TexasHospital not named in the registryTaking people
  • Irving, TexasHospital not named in the registryNo longer taking part
  • Jefferson City, MissouriHospital not named in the registryTaking people
  • Kansas City, MissouriHospital not named in the registryTaking people
  • Long Island City, New YorkHospital not named in the registryTaking people
  • Louisville, KentuckyHospital not named in the registryTaking people
  • McKinney, TexasHospital not named in the registryTaking people
  • Memphis, TennesseeHospital not named in the registryTaking people
  • Miami, FloridaHospital not named in the registryTaking people
  • Morehead City, North CarolinaHospital not named in the registryTaking people
  • New Hyde Park, New YorkHospital not named in the registryTaking people
  • New YorkHospital not named in the registryNo longer taking part
  • Norfolk, VirginiaHospital not named in the registryTaking people
  • Oklahoma City, OklahomaHospital not named in the registryTaking people
  • Raleigh, North CarolinaHospital not named in the registryTaking people
  • Reno, NevadaHospital not named in the registryTaking people
  • San Antonio, TexasHospital not named in the registryTaking people
  • St Louis, MissouriHospital not named in the registryTaking people
  • Topeka, KansasHospital not named in the registryTaking people
  • Tucson, ArizonaHospital not named in the registryTaking people
  • Williamsville, New YorkHospital not named in the registryTaking people

About the trial

What the trial wants to find out

This is a multi-center, global, randomized, double-blind, placebo-controlled Phase 2b study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves' disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment.

The 3 groups in the trial

  • IMVT-1402 Dose 1Treatment being tested

    Treatment: IMVT-1402

  • IMVT-1402 Dose 2Treatment being tested

    Treatment: IMVT-1402

  • PlaceboPlacebo, for comparison

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Patients With Graves' Disease
Plain-language title
IMVT-1402 for adults with Graves' disease who remain overactive despite treatmentGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT07018323, who can take part
Record updated
30 October 2026